PTC Therapeutics Inc. this month increased the list price of its muscular-dystrophy treatment by about 9%, to more than $65,000 annually for a common dosage.

The price increase again puts a spotlight on Emflaza, a decades-old steroidal drug that many U.S. patients had been paying $1,200 or less annually to import from Europe before the Food and Drug Administration last year approved the drug for U.S. sale as a treatment for Duchenne muscular dystrophy. The rare genetic disease affects up to 12,000 Americans, most of whom...  